Vis enkel innførsel

dc.contributor.authorScott, Jessica M.
dc.contributor.authorThomas, Samantha M.
dc.contributor.authorDouglas, Pamela S.
dc.contributor.authorYu, Anthony F.
dc.contributor.authorRusch, Valerie
dc.contributor.authorHuang, James
dc.contributor.authorCapaci, Catherine
dc.contributor.authorHarrison, Jenna N.
dc.contributor.authorStoeckel, Kurtis J.
dc.contributor.authorNilsen, Tormod Skogstad
dc.contributor.authorEdvardsen, Elisabeth
dc.contributor.authorMichalski, Meghan G.
dc.contributor.authorEves, Neil D.
dc.contributor.authorJones, Lee W.
dc.contributor.authorHerndon II, James E.
dc.date.accessioned2022-03-22T20:41:20Z
dc.date.available2022-03-22T20:41:20Z
dc.date.created2021-12-03T14:56:32Z
dc.date.issued2021
dc.identifier.citationJournal of Cachexia, Sarcopenia and Muscle. 2021, 12(6), Side 1456-1465.en_US
dc.identifier.issn2190-5991
dc.identifier.urihttps://hdl.handle.net/11250/2986912
dc.descriptionThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.en_US
dc.description.abstractBackground: Poor cardiorespiratory fitness (CRF) is a cardinal feature of post-treatment primary lung cancer. The most effective exercise therapy regimen to improve CRF has not been determined. Methods: In this parallel-group factorial randomized controlled trial, lung cancer survivors with poor CRF (below age–sex sedentary values) were randomly allocated to receive 48 consecutive supervised sessions thrice weekly of (i) aerobic training (AT)—cycle ergometry at 55% to >95% of peak oxygen consumption (VO2peak); (ii) resistance training (RT)—lower and upper extremity exercises at 50–85% of maximal strength; (iii) combination training (CT)—AT plus RT; or (iv) stretching attention control (AC) for 16 weeks. The primary endpoint was change in CRF (VO2peak, mL O2·kg−1·min−1). Secondary endpoints were body composition, muscle strength, patient-reported outcomes, tolerability (relative dose intensity of exercise), and safety. Analysis of covariance determined change in primary and secondary endpoints from baseline to post-intervention (Week 17) with adjustment for baseline values of the endpoint and other relevant clinical covariates. Results: Ninety patients (65 ± 9 years; 66% female) were randomized (AT, n = 24; RT, n = 23; CT, n = 20; and AC, n = 23) of the planned n = 160. No serious adverse events were observed. For the overall cohort, the lost-to-follow-up rate was 10%. Mean attendance was ≥75% in all groups. In intention-to-treat analysis, VO2peak increased 1.1 mL O2·kg−1·min−1 [95% confidence interval (CI): 0.0, 2.2, P = 0.04] and 1.4 mL O2·kg−1·min−1 (95% CI: 0.2, 2.5, P = 0.02) in AT and CT, respectively, compared with AC. There was no difference in VO2peak change between RT and AC (−0.1 mL O2·kg−1·min−1, 95% CI: −1.2, 1.0, P = 0.88). Favourable improvements in maximal strength and body composition were observed in RT and CT groups compared with AT and AC groups (Ps < 0.05). No between-group changes were observed for any patient-reported outcomes. Relative dose intensity of exercise was lower in RT and CT compared with AT (Ps < 0.05). Conclusions: In the context of a smaller than planned sample size, AT and CT significantly improved VO2peak in lung cancer survivors; however, the tolerability-to-benefit ratio was superior for AT and hence may be the preferred modality to target impaired CRF in post-treatment lung cancer survivors.en_US
dc.language.isoengen_US
dc.subjectaerobic trainingen_US
dc.subjectcancer survivorshipen_US
dc.subjectcombination trainingen_US
dc.subjectexercise capacityen_US
dc.subjectresistance trainingen_US
dc.titleEffects and tolerability of exercise therapy modality on cardiorespiratory fitness in lung cancer: A randomized controlled trialen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2021 The Authorsen_US
dc.source.pagenumber1456-1465en_US
dc.source.volume12en_US
dc.source.journalJournal of Cachexia, Sarcopenia and Muscleen_US
dc.source.issue6en_US
dc.identifier.doi10.1002/jcsm.12828
dc.identifier.cristin1964497
dc.description.localcodeInstitutt for fysisk prestasjonsevne / Department of Physical Performanceen_US
dc.description.localcodeInstitutt for idrettsmedisinske fag / Department of Sports Medicineen_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail
Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel